亚盛医药-B 将在 2023 年美国血液学会年会（ASH）展示奥雷巴替尼及 APG-2575 的多项临床进展。

Intelligent Finance News APP: Ascletis Pharma-B (06855) announced that its drugs Orelabatinib (trade name: Nalik®) and APG-2575 (Lisaftoclax) have made multiple clinical advancements and have been selected for presentation at the 65th Annual Meeting of the American Society of Hematology (ASH), with two of them being oral presentations. This marks the sixth consecutive year that Orelabatinib has been selected for an oral presentation at the ASH Annual Meeting, demonstrating the international hematology community's recognition of its efficacy and safety.

Orelabatinib (trade name: Nalik®) has broad potential in the treatment of various solid tumors and hematologic malignancies. Ascletis Pharma will present the latest progress of a randomized controlled registration Phase II study on the treatment of chronic myeloid leukemia in chronic phase (CML-CP) patients who are resistant to first- and second-generation tyrosine kinase inhibitors (TKIs). The study data showed that in CML-CP patients who were resistant or intolerant to previous TKIs, the Orelabatinib (trade name: Nalik®) treatment group demonstrated statistically and clinically significant improvements in event-free survival (EFS) compared to the control group receiving the best available therapy (BAT), achieving the primary endpoint of the study. Another oral presentation will be given by Professor Gong Xiaoyuan from the Hematology Hospital of the Chinese Academy of Medical Sciences, who will present the early results of a Phase II clinical trial on the treatment of newly diagnosed Ph+ ALL patients with Nalik in combination with Veenat and low-intensity chemotherapy.

The latest progress of the overseas clinical trials of Nalik will also be presented in the form of posters at this year's ASH Annual Meeting. The updated data shows that the monotherapy or combination therapy of Orelabatinib (trade name: Nalik®) is effective and safe in CML or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients who have undergone deep prior treatment, and once again confirms that the efficacy of Orelabatinib (trade name: Nalik®) in these patients is not affected by prior treatment with ponatinib or asciminib, further suggesting that this drug has the potential to provide a new effective treatment option for CML or Ph+ ALL patients worldwide.

In addition, other selected poster studies of Nalik include a series of case studies on the treatment of relapsed/refractory acute myeloid leukemia (AML) in children with liposomal mitoxantrone in combination with Veenat and high-dose tripterygium glycosides (MVHO regimen) (conducted by Hu Wenting and Professor Shen Shuhong from the Hematology Oncology Department of Shanghai Children's Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine), among other studies.

APG-2575 (Lisaftoclax) is a novel oral Bcl-2 selective inhibitor independently developed by Ascletis Pharma, with broad therapeutic potential in the treatment of various hematologic malignancies and solid tumors. The data on the treatment of chronic lymphocytic leukemia (CLL) patients with APG-2575 (Lisaftoclax) will be presented at this ASH Annual Meeting, once again demonstrating the significant efficacy and good tolerability of this drug in CLL patients who have previously received deep treatment and BTK therapy. In the other two selected abstracts by lisaftoclax, the efficacy and safety results of this drug in the treatment of relapsed/refractory (R/R) multiple myeloma (MM), AML, and other hematologic malignancies in monotherapy and combination therapy were disclosed.

The annual ASH meeting is one of the largest international academic conferences in the field of hematology, covering a comprehensive range of research on the etiology and treatment of blood diseases. The 65th ASH Annual Meeting will be held from December 9th to December 12th, 2023, in San Diego, USA, in a combination of offline and online formats.